Document is current
Any future updates will be listed below
-
Authors
Xia, Peiyi
Zhang, Lan
Li, Pan
Liu, Enjie
Li, Wencai
Zhang, Jianying
Li, Hui
Su, Xiaoxing
Jiang, Guozhong https://orcid.org/0000-0001-6306-726X
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 81272371)
Henan Programs for Science and Technology Development (No. 212102310134)
the National Science and Technology Major Project of China (No. 2018ZX10302205)
Zhengzhou Major Project for Collaborative Innovation (No. 18XTZX12007)
the Youth Innovation Fund of The First Affiliated Hospital of Zhengzhou University
- License Information
-
More Information
Article History
Received: 24 February 2021
Accepted: 11 July 2021
First Online: 16 July 2021
Declarations
:
: The study was approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University. All patients provided informed written consent for these genomic analyses.
: Informed consent was obtained from all individual participants included in the study, giving their authorization to access their clinical information and tumor samples for research purpose.
: Hui Li and Xiaoxing Su are the employees of Berry Oncology Corporation. All other authors declare no conflict of interests.
